GAPDHP29

Across TCGA pan-cancer cohorts, GAPDHP29 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated GAPDHP29 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher GAPDHP29 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated GAPDHP29 expression acts as an unfavorable survival marker, although some lineages such as COAD and READ show a favorable association.

CHOL, KIRP, and STAD are the cancer types where GAPDHP29 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.455	0.827	.003	86	view →
KIRP	DFS	Tertile	All	0.317	0.719	<.001	60	view →
STAD	DFS	Median	All	0.439	0.624	.003	47	view →
THCA	OS	Tertile	IV	0.770	0.972	<.001	45	view →
COAD	DFS	Tertile	All	0.874	0.723	.003	39	view →
DLBC	OS	Quartile	All	0.416	0.848	.006	17	view →
OV	OS	Median	II,III,IV	0.807	0.871	.012	16	view →
HNSC	OS	Tertile	IV	0.478	0.718	.031	14	view →
UVM	OS	Tertile	All	0.418	0.773	.032	12	view →
READ	OS	Median	All	1.000	0.805	.003	9	view →
LUAD	DFS	Quartile	II,III,IV	0.410	0.208	.019	7	view →
UCEC	DFS	Median	All	0.737	0.349	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

GAPDHP29–CHOL (OS)

Open the CHOL breakdown →